Compare ESTA & HTFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ESTA | HTFL |
|---|---|---|
| Founded | 2004 | 2007 |
| Country | United States | United States |
| Employees | N/A | 843 |
| Industry | Industrial Specialties | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.2B |
| IPO Year | 2018 | N/A |
| Metric | ESTA | HTFL |
|---|---|---|
| Price | $93.11 | $24.15 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | ★ $86.86 | $38.20 |
| AVG Volume (30 Days) | 682.5K | ★ 1.9M |
| Earning Date | 05-06-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 42.67 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $61,208,000.00 | N/A |
| Revenue This Year | $28.05 | $27.66 |
| Revenue Next Year | $26.21 | $23.55 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 76.49 | N/A |
| 52 Week Low | $33.35 | $20.13 |
| 52 Week High | $96.99 | $41.22 |
| Indicator | ESTA | HTFL |
|---|---|---|
| Relative Strength Index (RSI) | 60.16 | 37.67 |
| Support Level | $63.71 | $20.27 |
| Resistance Level | $92.84 | $25.05 |
| Average True Range (ATR) | 3.57 | 1.60 |
| MACD | -0.25 | -0.27 |
| Stochastic Oscillator | 66.63 | 9.26 |
Establishment Labs Holdings Inc is a medical technology company engaged in offering medical devices and aesthetic products. It is involved in the designing, manufacturing, and marketing of silicone-filled breast and body-shaping implants. The company markets its products under Motiva implants Brand. It distributes its products to medical distributors; and physicians, hospitals, and clinics in the form of direct sales. Its geographical segments are Europe, Latin America, Asia-Pacific/Middle East, and Others.
HeartFlow Inc is a commercial-stage medical technology company that provides software and artificial intelligence (AI) designed to deliver a non-invasive solution for diagnosing and managing coronary artery disease. The company operates and manages its business as a single reportable operating segment: non-invasive coronary artery disease detection solutions. Geographically, it operates in the United States and the rest of Europe, deriving the majority of its revenue from the United States. The company has developed three software products: Heartflow Roadmap Analysis, Heartflow FFRCT Analysis, and Heartflow Plaque Analysis.